Why a leading breast cancer surgeon sings to her patients | Laura Esserman | 14 comments One of the things that I love most is being able to sing my patients to sleep. It provides a welcome distraction from the operating room and also it gives people something to focus on other than the s...

One of the things I love most is being able to sing my patients to sleep.

Fierce 50 of 2025 | Laura Esserman I'm extremely grateful to get this award for leadership from Fierce Pharma. Back in 1993 no one had centers that integrated all the aspects of care for women, and women were frustrated at not having...

Thank you, Fierce Pharma!

“This is the future... And I want young people to feel like wow, there’s a hugely important and exciting area of study — and it’s prevention.” WISDOM founder Dr. Laura Esserman sat down with the San…... “This is the future... And I want young people to feel like wow, there’s a hugely important and exciting area of study — and it’s prevention.” WISDOM founder Dr. Laura Esserman sat down with the San ...

I always love talking about WISDOM!

#craaco2025 | Laura Esserman When clinical trials are personalized, more people want to be on them. Trials should look more like care, and care should look more like trials. Our systems for care and research need to be the same s...

Trials need to look more like care, and care needs to look more like trials.

I was honored to be the 50th Freyer Lecturer at the Sir Peter Freyer Surgical Symposium, talking about the path to personalized medicine and how to think about incorporating these principles into… | L... I was honored to be the 50th Freyer Lecturer at the Sir Peter Freyer Surgical Symposium, talking about the path to personalized medicine and how to think about incorporating these principles into your...

I had an amazing time at the Sir Peter Freyer Surgical Symposium, and was honored to be the 50th Freyer lecturer.

I had a great time talking to the South Australian Breast Cancer Study Group about the I-SPY trial. We talked about the journey of developing a way to individualize care based on response to improve… ... I had a great time talking to the South Australian Breast Cancer Study Group about the I-SPY trial. We talked about the journey of developing a way to individualize care based on response to improve o...

Thanks, SABCSG!

YouTube video by CBS Evening News Why a leading breast cancer surgeon sings to her patients

@cbseveningnews.bsky.social spotlight on @drlauraesserman.bsky.social @ucsfhealth.bsky.social
making the operating room more comfortable for patients. youtu.be/U6Jo91hYn4U?...

I had a great time giving the Florey Lecture at the University of Adelaide last week. It is time for us to think about personalizing treatment. We’ve been on a journey to personalize screening… | Lau... I had a great time giving the Florey Lecture at the University of Adelaide last week. It is time for us to think about personalizing treatment. We’ve been on a journey to personalize screening, becau...

I had a great time in Adelaide! Personalized medicine is the future, and the future is here.

Excited to reconnect with Aditya Bardia now that he is on the west coast. We will work on creating better regulatory endpoints for neoadjuvant breast cancer trials! | Laura Esserman Excited to reconnect with Aditya Bardia now that he is on the west coast. We will work on creating better regulatory endpoints for neoadjuvant breast cancer trials!

Lots of great work to do!

So fun meeting the residents and faculty at the UCLA Breast Surgery Program! Took the opportunity of giving Grand Rounds to cook up some great collaborations to work on through the awesome UC Athena… ... So fun meeting the residents and faculty at the UCLA Breast Surgery Program! Took the opportunity of giving Grand Rounds to cook up some great collaborations to work on through the awesome UC Athena N...

Lots of fun and great ideas at Grand Rounds at UCLA.

Excited to be part of this debate! Pragmatic randomized trials rule! | Laura Esserman Excited to be part of this debate! Pragmatic randomized trials rule!

Coming up—looking forward to it!

Cambria Nwosu, DNP, RN, LNC, CNOR(E), CSSM(E) on Instagram: "In an unprecedented move, the nation’s largest OB-GYN group is rejecting all federal funding in protest of Trump-era policy changes… |... I very much admire ACOG for having the courage to say that the policies that are being pursued are harming the health of women. There are huge disparities in outcomes in terms of breast cancer, matern...

Big kudos to ACOG.

Black women at higher risk of lymphedema due to axillary dissections | Laura Esserman posted on the topic | LinkedIn In medicine, we must look for disparities that lead to poor outcomes and work to fix them. Speaking of disparities, we identified that Black women are getting more axillary dissections than white wome...

We improve the field by finding and fixing disparities that lead to poor outcomes.

Lobular cancer: How molecular subtyping impacts treatment | Laura Esserman posted on the topic | LinkedIn Response predictive subtype and molecular subtyping matter in all subtypes, including lobular cancer. Women with lobular cancers who have molecularly high-risk disease are shown to benefit from neoadj...

Important ILC I-SPY paper.

Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial | JCO… | Laur... The data from I-SPY show clearly that immune subtyping matters and identifies high-risk breast cancer that’s hormone positive and clearly benefits from immunotherapy. This is the power of a long-stan...

New I-SPY paper!

Introducing OneSource: A New Approach to Cancer Care Data | Laura Esserman posted on the topic | LinkedIn Cancer care requires having a precise set of data that is shared amongst all clinicians and put together in ways that make it easy for clinicians to make decisions, for patients to understand their si...

Cancer care requires a precise set of data that is available to and used by clinicians.

Jen Dalton Local 12 News | Laura Esserman These are really important issues that will take center stage at the RISE UP for Breast Cancer Meeting, February 19-21. In two sessions, we will cover the use of hormone replacement therapy among wome...

Join us at Rise Up in February to discuss these and other important topics!

Check out this important paper from Kimberly Badal, PhD—learning how to apply screening in low-resource settings. | Laura Esserman Check out this important paper from Kimberly Badal, PhD—learning how to apply screening in low-resource settings. Lessons learned from the WISDOM breast cancer screening trial can be applied by unders...

Great new paper from Kim Badal!

The whole WISDOM team is in SF analyzing the results! | Laura Esserman The whole WISDOM team is in SF analyzing the results! News soon!

News to come!

Thrilled to bring together an awesome and fierce group of women from across the investment community on the third anniversary of Dobbs. | Laura Esserman Thrilled to bring together an awesome and fierce group of women from across the investment community on the third anniversary of Dobbs. These women have the courage and capacity to help us redefine th...

Join us in redefining the priorities for women’s health!

Another important publication showing that endocrine therapy is an important treatment for hormone-positive DCIS, showing that it is the most important long-term intervention to reduce the risk of… | ... Another important publication showing that endocrine therapy is an important treatment for hormone-positive DCIS, showing that it is the most important long-term intervention to reduce the risk of dev...

An important publication showing that endocrine therapy is the most important long-term intervention to reduce the risk of developing invasive breast cancer.

This paper shows that there is a subset of hormone-positive patients that have an immune signature and respond to chemo and immunotherapy, as well as triple-negative patients that have an immune… | La... This paper shows that there is a subset of hormone-positive patients that have an immune signature and respond to chemo and immunotherapy, as well as triple-negative patients that have an immune signa...

An important step on the road to personalizing treatments for women with breast cancer!

Naseem—thank you for your energy and leadership. | Laura Esserman Naseem—thank you for your energy and leadership. VC Guerrieres unite!

The future of women’s health is here.

Check out this AMAZING result. | Laura Esserman Check out this AMAZING result.   889 patients with colon cancer were randomized to a structured exercise program versus a health education group about the value of exercise after adjuvant therapy for ...

Big kudos to the Canadian Cancer Society for funding this critically important study, and to the CHALLENGE investigators for carrying it out.

At the BCC and beyond, we are aspiring to train the future leaders in healthcare, who will drive innovation in healthcare value. | Laura Esserman At the BCC and beyond, we are aspiring to train the future leaders in healthcare, who will drive innovation in healthcare value. This year’s intern reunion, Sparking Innovation, was on Saturday, June ...

Sparking Innovation in Healthcare Value—always inspiring!

NIH grant funding restored Judge rules grant terminations on the basis of DEI and gender identity are discriminatory and illegal

It is a relief that someone said it, "how have we fallen so low?"

www.ifyoucankeepit.org/p/breaking-n...

Judy Boughey's presidential address highlighted how important innovative trial design is for moving the field forward and talked about I SPY 2.2.- even though it is more complex, it is a wonderful way to treat patients

Mandeep Kaur presenting on the disparity in the use of axillary dissection by race at ASBrS 2025

Julie van Hassel (award for best trainee) presented on the time to surgery after neoadjuvant chemo and impact on outcomes

(In the setting of excellent response, time is not important, but in setting of residual disease, > 9 weeks is associated with worse outcome)

Rita Mukhtar and down staging of the axilla in lobular vs. ductal on I SPY at ASBrS 2025